BR0206847A - Tratamento do diabete melito - Google Patents
Tratamento do diabete melitoInfo
- Publication number
- BR0206847A BR0206847A BR0206847-8A BR0206847A BR0206847A BR 0206847 A BR0206847 A BR 0206847A BR 0206847 A BR0206847 A BR 0206847A BR 0206847 A BR0206847 A BR 0206847A
- Authority
- BR
- Brazil
- Prior art keywords
- diabetes mellitus
- treatment
- mellitus treatment
- melito
- diabete
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 abstract 1
- 238000009109 curative therapy Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002638 palliative care Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 229960002381 vardenafil Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26608301P | 2001-02-02 | 2001-02-02 | |
| GB0106468A GB0106468D0 (en) | 2001-03-15 | 2001-03-15 | Treatment of diabetes mellitus |
| PCT/IB2002/000315 WO2002060422A2 (en) | 2001-02-02 | 2002-01-30 | Treatment of diabetes mellitus using vardenafil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0206847A true BR0206847A (pt) | 2004-02-25 |
Family
ID=26245830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0206847-8A BR0206847A (pt) | 2001-02-02 | 2002-01-30 | Tratamento do diabete melito |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6683080B2 (https=) |
| EP (1) | EP1355651A2 (https=) |
| JP (1) | JP2004527476A (https=) |
| AU (1) | AU2002226633A1 (https=) |
| BR (1) | BR0206847A (https=) |
| CA (1) | CA2436576A1 (https=) |
| MX (1) | MXPA03006936A (https=) |
| WO (1) | WO2002060422A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020165237A1 (en) * | 2000-08-11 | 2002-11-07 | Fryburg David Albert | Treatment of the insulin resistance syndrome |
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
| JP2005508978A (ja) * | 2001-11-02 | 2005-04-07 | ファイザー・プロダクツ・インク | Ｐｄｅ９阻害薬によるインスリン抵抗性症候群及び２型糖尿病の治療 |
| US20030181461A1 (en) * | 2002-01-25 | 2003-09-25 | Lautt Wilfred Wayne | Use of phosphodiesterase antagonists to treat insulin resistance |
| US20040077650A1 (en) * | 2002-10-18 | 2004-04-22 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| BRPI0408500A (pt) * | 2003-03-17 | 2006-03-07 | Pfizer Prod Inc | tratamento do diabetes do tipo 1 com inibidores de pde5 |
| DE10325813B4 (de) * | 2003-06-06 | 2007-12-20 | Universitätsklinikum Freiburg | Prophylaxe und/oder Therapie bei der portalen Hypertonie |
| DE102004023069A1 (de) * | 2004-05-11 | 2005-12-08 | Bayer Healthcare Ag | Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil |
| WO2006074443A2 (en) * | 2005-01-07 | 2006-07-13 | The Johns Hopkins University | Pde5 inhibitor compositions and methods for immunotherapy |
| US20060235005A1 (en) * | 2005-04-14 | 2006-10-19 | Oak Labs, Corp. | Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia |
| DE102005018389A1 (de) * | 2005-04-20 | 2006-10-26 | Sanofi-Aventis Deutschland Gmbh | Azolderivate als Inhibitoren von Lipasen und Phospholipasen |
| WO2007010337A2 (de) * | 2005-07-15 | 2007-01-25 | Proxomed Medizintechnik Gmbh | Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von adipositas, sowie abgabesysteme für dieselben |
| WO2008028914A1 (en) | 2006-09-07 | 2008-03-13 | Nycomed Gmbh | Combination treatment for diabetes mellitus |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| US8969514B2 (en) * | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| KR101560844B1 (ko) | 2007-06-04 | 2015-10-15 | 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 | 트라이-아릴계 화합물 및 이를 포함하는 조성물 |
| ES2522968T3 (es) * | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| US20100221329A1 (en) | 2008-12-03 | 2010-09-02 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| US8592370B2 (en) * | 2008-12-12 | 2013-11-26 | Poxel S.A.S. | Combination of insulin with triazine derivatives |
| JP2013508295A (ja) | 2009-10-16 | 2013-03-07 | デューク・ユニヴァーシティ | 薬物誘発性手足症候群を治療するための組成物および方法 |
| US8637096B2 (en) | 2009-12-04 | 2014-01-28 | Curtis C. Stojan | Compositions and method for enhancing insulin activity |
| WO2011162320A1 (ja) * | 2010-06-23 | 2011-12-29 | 国立大学法人九州大学 | Egcgまたはメチル化egcgとpde阻害剤との組み合わせ |
| WO2012037380A2 (en) | 2010-09-15 | 2012-03-22 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| AT512084A1 (de) | 2011-10-20 | 2013-05-15 | Univ Wien Tech | Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren |
| WO2013106547A1 (en) * | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| AU2014235215A1 (en) | 2013-03-15 | 2015-10-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| MX2016005995A (es) | 2013-11-05 | 2016-08-17 | Ben-Gurion Univ Of The Negev Res And Dev Authority | Compuestos para el tratamiento de diabetes y complicaciones de la enfermedad derivadas de la misma. |
| WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2395558C (en) | 1997-11-12 | 2007-07-17 | Bayer Aktiengesellschaft | Intermediates for 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| KR20010052235A (ko) * | 1998-04-06 | 2001-06-25 | 후지야마 아키라 | 인돌 유도체 |
| DE19944161A1 (de) | 1999-09-15 | 2001-03-22 | Bayer Ag | Neue Kombination zur Behandlung von sexueller Dysfunktion |
| ATE257480T1 (de) * | 1999-09-30 | 2004-01-15 | Pfizer Prod Inc | Bicyclische pyrrolylamide als glycogenphosphorylase-inhibitoren |
| AU2001219185A1 (en) | 2000-03-17 | 2001-10-03 | Alcon, Inc. | 2-acylaminobenzimidazole derivatives for treating glaucoma |
| US6774128B2 (en) | 2000-04-19 | 2004-08-10 | Johns Hopkins University | Methods for prevention and treatment of gastrointestinal disorders |
| WO2001088824A2 (en) | 2000-05-15 | 2001-11-22 | Imakit, Ltd. | Method and system for online custom footwear preparation |
| AU2001276607A1 (en) * | 2000-08-11 | 2002-02-25 | Pfizer Inc. | Treatment of the insulin resistance syndrome with selective CGMP PDE5 inhibitors |
-
2002
- 2002-01-30 MX MXPA03006936A patent/MXPA03006936A/es unknown
- 2002-01-30 JP JP2002560615A patent/JP2004527476A/ja not_active Withdrawn
- 2002-01-30 WO PCT/IB2002/000315 patent/WO2002060422A2/en not_active Ceased
- 2002-01-30 AU AU2002226633A patent/AU2002226633A1/en not_active Abandoned
- 2002-01-30 BR BR0206847-8A patent/BR0206847A/pt not_active IP Right Cessation
- 2002-01-30 EP EP02716245A patent/EP1355651A2/en not_active Withdrawn
- 2002-01-30 US US10/060,788 patent/US6683080B2/en not_active Expired - Fee Related
- 2002-01-30 CA CA002436576A patent/CA2436576A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6683080B2 (en) | 2004-01-27 |
| AU2002226633A1 (en) | 2002-08-12 |
| EP1355651A2 (en) | 2003-10-29 |
| MXPA03006936A (es) | 2003-11-18 |
| WO2002060422A2 (en) | 2002-08-08 |
| US20020143015A1 (en) | 2002-10-03 |
| WO2002060422A3 (en) | 2002-10-10 |
| JP2004527476A (ja) | 2004-09-09 |
| CA2436576A1 (en) | 2002-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0206847A (pt) | Tratamento do diabete melito | |
| CL2004001069A1 (es) | Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii. | |
| BR9714082A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto. | |
| BR9911482A (pt) | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto | |
| HN2002000275A (es) | Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados | |
| CL2004000889A1 (es) | COMPUESTOS DERIVADOS DE PIRAZOLO[4,3-d]PIRIMIDINA; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; PROCEDIMIENTO DE PREPARACION Y SU USO EN LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA HIPERTENSION. | |
| HUP0101158A3 (en) | Use of glycogen phosphorylase inhibitors for the preparation of pharmaceutical compositions for the prophylactic treatment of type 2 diabetes mellitus | |
| EG24124A (en) | Pharmaceutical compositions for the treatment of type-II diabetes mellitus | |
| DOP2002000429A (es) | Imidazotriazinas | |
| ATE231872T1 (de) | Thiazolopyrimidinderivate | |
| BR0112962B1 (pt) | Composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos | |
| TW200505875A (en) | Novel compounds | |
| ITMI20031570A1 (it) | Composizione per uso dietetico, farmaceutico o cosmetico | |
| DE60336225D1 (de) | Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend | |
| DE60202590D1 (de) | 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen | |
| DE60108354D1 (de) | 2H-1-Benzopyran-Derivative, Prozesse zu ihrer Herstellung und Pharmazeutische Zusammensetzungen | |
| BR0212249A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto | |
| NO984476L (no) | Sulfonamidsubstituerte kromaner, fremgangsmÕte for fremstilling derav, deres anvendelse som medikament samt farmas°ytiske preparater inneholdende forbindelsene | |
| ID21282A (id) | Senyawa-senyawa cincin beranggota-5 terpadu yang disubstitusi sulfonamida, penggunaannya sebagai obat, dan sediaan farmasi yang mengandung senyawa tersebut | |
| BR0214487A (pt) | Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes | |
| ES2175661T3 (es) | Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen. | |
| AU9743698A (en) | Allelic variant of human stat3 | |
| NO984475L (no) | Sulfonamidsubstituerte kromaner, fremgangsmÕte for fremstilling derav, deres anvendelse som medikament samt farmas°ytiske preparater inneholdende forbindelsene | |
| BRPI0416105A (pt) | uso da bh4 para o tratamento de doença respiratórias | |
| BR0211827A (pt) | Uso de inibidores de il-18 em distúrbios de hipersensibilidade |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A , 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2055 DE 25/05/2010. |